HCoV-NL63 and SARS-CoV-2 Share Recognized Epitopes by the Humoral Response in Sera of People Collected Pre- and during CoV-2 Pandemic.
HCoV-NL63 and SARS-CoV-2 Share Recognized Epitopes by the Humoral Response in Sera of People Collected Pre- and during CoV-2 Pandemic.
复制标题
DOI：
10.3390/microorganisms8121993
复制
发表时间：
2020-12-14
期刊：
影响因子：
4.5
通讯作者：
Sechi LA
中科院分区：
文献类型：
--
作者：
Simula ER;Manca MA;Jasemi S;Uzzau S;Rubino S;Manchia P;Bitti A;Palermo M;Sechi LA
严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）可导致老年人和患有慢性基础疾病的人患上严重疾病;然而，儿童和年轻人通常无症状或症状轻微。我们评估了针对人冠状病毒NL 63的特异性抗体（Abs）反应的存在（HCoV-NL 63）S蛋白表位（NL 63-RBM 1、NL 63-RBM2_1、NL 63-RBM2_2、NL 63-RBM 3、NL 63-SPIKE 541 -554和NL 63-DISC-like）和SARS-CoV-2表位通过间接ELISA检测大流行前、大流行中期和COVID-19队列血浆样本中的COV 2-SPIKE 421 -434和COV 2-SPIKE 742 -759。此外，进行竞争性测定以检查在具有SARS-CoV-2的明确诊断的患者中COV 2-SPIKE 421 -434和NL 63-RBM 3之间的交叉反应性应答。对所有SARS-CoV-2和HCoV-NL 63表位的免疫反应显示，与大流行中期患者相比，大流行前患者的反应显著更高。结果表明，可能针对HCoV-NL 63的抗体可能能够与SARS-CoV-2表位交叉反应，并且在大流行前的较高发病率可能是由于HCoV-NL 63高发病率报告时的采集时间。此外，竞争性测定显示针对COV 2-SPIKE 421 -434和NL 63-RBM 3肽的抗体之间的交叉反应性。在大流行前和大流行中期的个体中均检测到预先存在的HCoV-NL 63抗体应答与SARS-CoV-2交叉反应，这表明先前暴露于HCoV-NL 63表位可能产生抗体，这些抗体可以赋予针对SARS-CoV-2的保护性免疫，并可能降低疾病的严重程度。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause serious illness in older adults and people with chronic underlying medical conditions; however, children and young people are often asymptomatic or with mild symptoms. We evaluated the presence of specific antibodies (Abs) response against Human coronavirus NL63 (HCoV-NL63) S protein epitopes (NL63-RBM1, NL63-RBM2_1, NL63-RBM2_2, NL63-RBM3, NL63-SPIKE541–554, and NL63-DISC-like) and SARS-CoV-2 epitopes (COV2-SPIKE421–434 and COV2-SPIKE742–759) in plasma samples of pre-pandemic, mid-pandemic, and COVID-19 cohorts by indirect ELISA. Moreover, a competitive assay was performed to check for cross reactivity response between COV2-SPIKE421–434 and NL63-RBM3 among patients with a definitive diagnosis of SARS-CoV-2. Immune reaction against all SARS-CoV-2 and HCoV-NL63 epitopes showed a significantly higher response in pre-pandemic patients compared to mid-pandemic patients. The results indicate that probably antibodies against HCoV-NL63 may be able to cross react with SARS-CoV-2 epitopes and the higher incidence in pre-pandemic was probably due to the timing of collection when a high incidence of HCoV-NL63 is reported. In addition, the competitive assay showed cross-reactivity between antibodies directed against COV2-SPIKE421–434 and NL63-RBM3 peptides. Pre-existing HCoV-NL63 antibody response cross reacting with SARS-CoV-2 has been detected in both pre- and mid-pandemic individual, suggesting that previous exposure to HCoV-NL63 epitopes may produce antibodies which could confer a protective immunity against SARS-CoV-2 and probably reduce the severity of the disease.
登录
查看更多内容
影响因子：
9.4
作者：
Dijkman, Ronald;Jebbink, Maarten F.;van der Hoek, Lia
通讯作者：
van der Hoek, Lia
影响因子：
56.9
作者：
Kissler, Stephen M.;Tedijanto, Christine;Lipsitch, Marc
通讯作者：
Lipsitch, Marc
影响因子：
12.7
作者：
Canducci, Filippo;Debiaggi, Maurizia;Clementi, Massimo
通讯作者：
Clementi, Massimo
DOI：
10.18632/aging.104166
发表时间：
2020-10-13
期刊：
Aging
影响因子：
--
作者：
Sotgia F;Lisanti MP
通讯作者：
Lisanti MP
影响因子：
24.8
作者：
Premkumar, Lakshmanane;Segovia-Chumbez, Bruno;de Silva, Aravinda M.
通讯作者：
de Silva, Aravinda M.